HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Dexamethasone (Maxidex)

Subscribe to New Research on Dexamethasone

An anti-inflammatory 9-fluoro-glucocorticoid.

Also Known As:

Maxidex; Decaspray; Alcon Brand of Dexamethasone; Decaject; Decaject-L.A.; Decameth; Dexasone; Dexpak; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol; ICN Brand of Dexamethasone; Merck Brand of Dexamethasone; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Methylfluorprednisolone; Millicorten; Oradexon; Decaject L.A.; Hexadecadrol; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-

Networked: 11870 relevant articles (1279 outcomes, 1876 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 55
- Steroids: 16079
  - Fluorinated Steroids: 24
    - Dexamethasone: 11870
  - Pregnanes: 3
    - Pregnadienes
      - Pregnadienetriols
        Dexamethasone: 11870
        dexamethasone 21-phosphate: 61
        dexamethasone acetate: 30
        VAD regimen: 27
        Dexa-BEAM protocol: 21
        BB 1101: 11
        Dexamethasone Isonicotinate: 11
        dexamethasone 21-methanesulfonate: 10
        vitamin B12 drug combination thiamine phenylbutazone dexamethasone aminopyrine: 6
        corticosteroid methanetriol mixture: 5
        Otomize: 5
        Sofradex: 4
        VAD protocol: 4
        auricularum: 3
        dexamethasone 17-valerate: 3
        Baycuten: 2
        Dexa-Rhinospray: 2
        dexamethasone glucuronide: 2
        exosterol: 2
        PD protocol: 2
        polymyxin B drug combination neomycin dexamethasone: 2
        21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione: 1
        ALL-VI protocol: 1
        Berlin-Frankfurt-Muenster protocol II: 1
        bovicystan: 1
        CEVAD protocol: 1
        CHASE protocol: 1
        CMED protocol: 1
        COMD combination: 1
        covomycin D: 1
        CVAD protocol: 1
        DAI protocol: 1
        DCEP protocol: 1
        Dexa-PAMB protocol: 1
        dexafen: 1
        dexamethasone 21-palmitate: 1
        dexamethasone linoleate: 1
        dexamethasone oxetanone: 1
        dexamethasone succinate dextran: 1
        dexamethasone trimethyl acetate: 1
        DHACT protocol: 1
        DHAP protocol: 1
        Doxiproct Plus: 1
        FLUDAP protocol: 1
        M-BACOD protocol: 1
        modified ESHAP regimen: 1
        supertendin: 1
        Tresaderm: 1
        TVTG protocol: 1
        VMD protocol: 1
        11-dehydrodexamethasone
        11-ketodexamethasone
        21-((aminopropyl)thio)dexamethasone
        21-((mercaptobutyl)thio)dexamethasone
        4-(carboxymethylthio)dexamethasone
        6-hydroxydexamethasone
        6-hydroxydexamethasone 17-propionate
        ALL-85 protocol
        azimycin
        BACOD protocol
        BACOD-VP16 protocol
        BBVDD protocol
        BFM-ALL 81 protocol
        BMPD protocol
        CAD protocol 3
        CBVD protocol
        CEOP-IMVP-Dexa regimen
        CEVD protocol
        CIOD protocol
        Cis-VACD protocol
        CMD protocol
        CODBLAM IV protocol
        Corto-Tavegil
        CVAD-V protocol
        DCTER protocol
        DEMOB protocol
        dexa-phebrocon
        dexamethasone 17-propionate
        dexamethasone 21-(beta-isothiocyanatoethyl)thioether
        dexamethasone 21-bromoacetate
        dexamethasone 21-glucoside
        dexamethasone 21-iodoacetate
        dexamethasone 21-phenylpropionate
        dexamethasone 21-tributylacetate
        dexamethasone dipropionate
        dexamethasone sulfate ester
        dexamethasone trioxa undecanoate
        dexamethasone-17-carboxamide
        dexamethasone-21-sulfobenzoate
        dexamethasone-beta-cyclodextrin
        dexamethasone-bis-peptide nucleic acid
        dexamethasone-FK506 heterodimer
        DFCI 91-01 protocol
        DFCI 95-01 protocol
        DHAOx protocol
        DICE protocol
        DIZE protocol
        DT PACE regimen
        DT-PACE protocol
        EDAP regimen
        EVDAC regimen

Experts

1.	Anderson, Kenneth C: 23 articles (08/2012 - 03/2002)
2.	Rajkumar, S Vincent: 17 articles (07/2012 - 11/2002)
3.	Dispenzieri, Angela: 13 articles (06/2012 - 01/2002)
4.	Richardson, Paul G: 12 articles (08/2012 - 06/2002)
5.	Gertz, Morie A: 12 articles (02/2012 - 01/2002)
6.	van de Beek, Diederik: 11 articles (11/2012 - 11/2002)
7.	Whitcup, Scott M: 11 articles (11/2012 - 03/2007)
8.	Dimopoulos, M A: 11 articles (10/2012 - 07/2001)
9.	Hideshima, Teru: 11 articles (08/2012 - 06/2002)
10.	Harousseau, Jean-Luc: 11 articles (06/2012 - 02/2006)

Related Diseases

1.	Vomiting 04/01/2008 - "A significant reduction in vomiting from 27% to 11% was achieved following the introduction of routine use of intravenous dexamethasone during surgery. " 04/01/2003 - "Compared with placebo, dexamethasone significantly decreased the incidence of early and late vomiting (P < 0.05, P < 0.001 respectively). " 02/01/1995 - "Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. " 01/01/1998 - "Six patients in group D and 19 in group S experienced vomiting at least once within the 24-h postoperative period; dexamethasone was effective in reducing the overall incidence of vomiting from 63.3% to 20.0% (P < 0.01). " 10/01/2000 - "Dexamethasone is clearly effective in protecting from emesis both in the acute and delayed phases, with emesis avoided in one patient out of six treated. " Order ALL the reference details at left...
2.	Multiple Myeloma 01/01/1998 - "The authors describe a case of multiple myeloma in which a complete remission was obtained by treatment with high dose dexamethasone. " 10/01/2009 - "The high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment." 02/01/1999 - "The use of biological modifiers in combination with dexamethasone offer a safe and effective therapeutic option in patients with refractory multiple myeloma. " 11/01/2009 - "In this brief report, we review these findings and introduce the multiple myeloma cells as a novel system to study autophagy in response to dexamethasone." 07/01/2009 - "Our aim in the present study was to use genomic screening to identify genes targeted for epigenetic inactivation in multiple myeloma and assess their role in the development of resistance to dexamethasone. " Order ALL the reference details at left...
3.	Postoperative Nausea and Vomiting (PONV) 02/01/2001 - "Of them, dexamethasone used as a prophylactic drug for PONV provided the best results. " 01/01/2008 - "Dexamethasone has been proven effective in the prophylaxis of late PONV. " 08/01/2007 - "A single dose of dexamethasone significantly decreased the incidence of postoperative vomiting in early and late recovery phase and shortened the time to first oral intake and the duration of IV therapy." 03/01/2001 - "Dexamethasone significantly decreased the incidence of postoperative vomiting during the first 24 h, shortened the time to the first oral intake and the duration of IV hydration, and improved the quality of oral intake and the satisfaction scores of the patients." 07/01/1998 - "Compared with placebo, dexamethasone significantly decreased the incidence of PONV in the 24 h after discharge, improved oral intake, decreased the frequency of parental phone calls, and resulted in no hospital returns for the management of PONV and/or poor oral intake." Order ALL the reference details at left...
4.	Nausea 01/01/2009 - "Seven patients (18%) in the dexamethasone group reported nausea, compared with 16 (40%) in the placebo group (p = 0.026). " 04/01/2008 - "Seven patients in the control group, but only one in the dexamethasone group, were treated for nausea (P = 0.05). " 04/01/2007 - "Average nausea scores were low in all groups, but the incidence of nausea until 24 h postoperatively was significantly higher among groups receiving only 2 mg of dexamethasone (P < 0.03). " 01/01/2006 - "In the dexamethasone-plus-ginger-treated group, 12 patients experienced nausea, one patient retched, four patients vomited once, no patients vomited repeatedly, and 13 patients required a rescue antiemetic. " 01/01/2006 - "In the dexamethasone-treated group, 14 patients experienced nausea, two patients retched, three patients vomited once, two patients vomited repeatedly, and 14 patients required a rescue antiemetic. " Order ALL the reference details at left...
5.	Neoplasms (Cancer) 06/01/2005 - "However, despite frequent initial complete remission, prolonged dexamethasone treatment results in the appearance of chemoresistant tumor cells and most patients with MM ultimately present relapse of the underlying disease. " 04/22/1993 - "These studies establish that a dexamethasone-inducible family 3A P450 can make an important contribution to rat liver microsomal ifosphamide activation, and suggest that dexamethasone pretreatment might provide a useful approach for modulation of ifosphamide metabolism in order to improve its therapeutic efficacy in cancer patients." 01/01/2012 - "However, CsA (4 mg/kg/day) plus dexamethasone treatment resulted in a dramatic regression of the tumors and amelioration of systemic symptoms and induced complete remission (CR) within 2 weeks. " 01/01/2008 - "In vivo, we saw good therapeutic efficacy of the viruses in a model of intravenous therapy of metastatic cervical cancer, but the inhibitory effect of dexamethasone was not strong enough to provide significant differences in a complex in vivo environment. " 03/01/2009 - "The anti-tumor activity of dexamethasone derivatives (9-fluoro-16alpha-methyl-11,17-dihydroxy-3-oxo-1,4-androsladiene-17beta-carboxylic acid) is superior to that of dexamethasone. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Cisplatin (Platino)
3.	Cyclophosphamide (Cytoxan)
4.	bortezomib (Velcade)
5.	Metoclopramide (Reglan)
6.	Doxorubicin (Adriamycin)
7.	Vincristine (Oncovin)
8.	Thalidomide (Thalomid)
9.	Granisetron (Kytril)
10.	Hydrocortisone (Cortisol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	Aftercare (After-Treatment)
4.	Injections
5.	Oral Administration

blog comments powered by Disqus

TREATMENT OPTIONS
for Vomiting,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1458 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>